Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
The objective of this study is to evaluate the safety and effectiveness of Humira®
 (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis
 patients under a routine treatment practice.
Inclusion Criteria:

 -  Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis

 -  Patients voluntarily signed a patient authorization & informed consent form.

 -  Decision on the treatment with Humira® was made prior to any decision to approach the
 patient to participate in this study.

 -  Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC)
 and professional and/or reimbursement guidelines.

 Exclusion Criteria:

 -  A patient who are contraindications to originator adalimumab (Humira®) as listed on
 the approved Korean label.

 -  A patient who is participating on other interventional clinical trials

 -  Prior treatment with Humira®, including current course of Humira® started prior to
 baseline visit assessments.